553030 Sigma-AldrichRAGE Antagonist, FPS-ZM1 - CAS 945714-67-0 - Calbiochem
RAGE Antagonist, FPS-ZM1, is a blood-brain-barrier permeant blocker of RAGE V domain-mediated ligand binding (Ki = 25, 148, & 230 nM, respectively, against Aβ40, HMGB1 & S100B, binding to sRAGE).
More>> RAGE Antagonist, FPS-ZM1, is a blood-brain-barrier permeant blocker of RAGE V domain-mediated ligand binding (Ki = 25, 148, & 230 nM, respectively, against Aβ40, HMGB1 & S100B, binding to sRAGE). Less<<Synonyms: Receptor for AGE Antagonist, FPS-ZM1, N-Benzyl-4-chloro-N-cyclohexylbenzamide
Recommended Products
Overview
Replacement Information |
---|
Key Spec Table
CAS # | Empirical Formula |
---|---|
945714-67-0 | C₂₀H₂₂ClNO |
Products
Catalogue Number | Packaging | Qty/Pack | |
---|---|---|---|
553030-25MG | Glass bottle | 25 mg |
References | |
---|---|
References | Deane, R., et al. 2012. J. Clin. Invest. 122, 1377. |
Product Information | |
---|---|
CAS number | 945714-67-0 |
Form | White to off-white semi-solid or viscous liquid |
Hill Formula | C₂₀H₂₂ClNO |
Reversible | Y |
Structure formula Image | |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | RAGE |
Primary Target K<sub>i</sub> | 25, 148, and 230 nM, respectively, against A&beta |
Purity | ≥98% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalogue Number | GTIN |
553030-25MG | 04055977193466 |
Documentation
RAGE Antagonist, FPS-ZM1 - CAS 945714-67-0 - Calbiochem SDS
Title |
---|
RAGE Antagonist, FPS-ZM1 - CAS 945714-67-0 - Calbiochem Certificates of Analysis
Title | Lot Number |
---|---|
553030 |
References
Reference overview |
---|
Deane, R., et al. 2012. J. Clin. Invest. 122, 1377. |